跳至主要内容
临床试验/ACTRN12620000794909
ACTRN12620000794909尚未招募4 期

A retreatment study to determine the efficacy of MAVIRET (Glecaprevir/Pibrentasvir) and generic sofosbuvir for 16 weeks in hepatitis C patients with NS5A resistance who did not respond to previous VIEKIRA PAK or MAVIRET or ZEPATIER treatment.

Auckland District Health Board0 个研究点目标入组 75 人开始时间: 2020年8月7日最近更新:
适应症

试验速览

阶段
4 期
状态
尚未招募
入组人数
75

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Confirmed prior treatment with VIEKIRA PAK or MAVIRET or ZEPATIER
  • - Confirmed failure of VIEKIRA PAK or MAVIRET or ZEPATIER as demonstrated by positive viral load at greater than or equal to (=) 12 weeks after end of treatment (SVR12) and no history of continued injecting drug use to suggest reinfection
  • - Confirmed NS5A resistance demonstrated

排除标准

  • - Severe hepatic impairment classed as Child-Pugh C decompensated cirrhosis. Patients with moderate hepatic impairment classed as Child-Pugh B decompensated cirrhosis will be considered on a case-by-case basis.

研究者

相似试验